LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeuticsfor the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2018 financial results on Tuesday, March 26, 2019, after the close of the US markets. Management will host a conference
To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the investors section of the Curis website at www.curis.com. A replay will also be available on the Curis website shortly after completion of the call.
About Curis, Inc. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors lymphomas and mesothelioma, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing ErivedgeŽ for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
View original content:http://www.prnewswire.com/news-releases/curis-to-release-fourth-quarter-and-year-end-2018-financial-results-and-host-conference-call-on-march-26-2019-300817490.html
SOURCE Curis, Inc.
Subscribe to our Free Newsletters!